Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in the glucose-sensitivity of the beta cells
研究概览
简要总结
The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Weight 50-100 kg
排除标准
- •Chronic disease
- •Concomitant drug use
- •Pregnancy or lactation
- •Fasting glucose >6 mmol/L.
研究组 & 干预措施
Liraglutide
Liraglutide 0.6 mg/day subcutaneously.
干预措施: Liraglutide (Drug)
结局指标
主要结局
Change in the glucose-sensitivity of the beta cells
时间窗: baseline, first dose, after 3-weeks on treatment
Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment).
次要结局
- Effects on adrenal hormones(baseline, acute administration, 3 weeks)
研究者
Vallo Volke
Professor
University of Tartu